Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million

Reuters

2025/11/07

Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million

Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581501208"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581501208\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581501208?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581501208","market":"nz","top_or_hot":-1,"title":"Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbfQFvL:1","article_id":"2581501208","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581501208","pubTimestamp":1762462971,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $ million, while Adjusted EBITDA was $ million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $ million, compared to $ million last year, with Adjusted EBITDA at $ million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc.","BK4121":"生命科学工具和服务"},"translate_title":"Maravai LifeSciences报告第三季度收入为4160万美元，净亏损为4510万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":0.9},"content_text":"Maravai LifeSciences reports Q3 revenue of $41.6 million and net loss of $45.1 million\n    \n\n        Maravai LifeSciences Holdings Inc. reported revenue of $41.6 million for the third quarter ended September 30, 2025, compared to $69.0 million in the same period in 2024. Net loss for the quarter was $(45.1) million, while Adjusted EBITDA was $(10.8) million. For the nine months ended September 30, 2025, revenue totaled $135.9 million, down from $202.6 million in the prior year period. Net loss for the nine-month period was $(167.7) million, compared to $(213.6) million last year, with Adjusted EBITDA at $(31.7) million versus $37.0 million in 2024. The company expects full year 2025 revenue of approximately $185.0 million. Maravai continues organizational restructuring and cost reduction initiatives, with Cygnus performing well and TriLink expected to achieve double-digit sequential revenue growth in the fourth quarter.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106112818) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}